Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
2.8
Journals
Healthcare
Special Issues
Interventional Cardiology as a Tool for Improving the Quality of...
share announcement

Interventional Cardiology as a Tool for Improving the Quality of Life and Prognosis of Cardiac Patients

A special issue of Healthcare (ISSN 2227-9032). This special issue belongs to the section "Healthcare Quality and Patient Safety".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 3045

Special Issue Editor

Dr. Marcin Kozuch

E-Mail Website
Guest Editor
Department of Invasive Cardiology, Medical University of Bialystok, 24A Sklodowskiej-Curie St., 15-276 Bialystok, Poland
Interests: interventional cardiology; myocardial infarction; experimental cardiology; cardiac surgery

Special Issue Information

Dear Colleagues,

Although modern interventional cardiology has contributed to improving the quality of life and prognosis of cardiological patients, further progress must be made to improve treatment. This Special Issue aims to present the latest knowledge on factors and markers affecting the quality of life and prognosis of patients with coronary artery disease and structural disorders who have undergone interventional treatment. We invite you to present the results of your innovative research, and hope that this will expand current knowledge on this topic and contribute to improving the quality of life and prognosis of patients with myocardial infarction, chronic coronary syndromes, atrial fibrillation (left atrial appendage closure), and valvular heart disease (TAVI). This Special Issue of Healthcare welcomes both typical clinical trials and the presentation of new biochemical markers in this field.

Sincerely,
Dr. Marcin Kozuch
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • percutaneous coronary intervention
  • prognosis
  • revascularization
  • myocardial infarction
  • chronic coronary syndromes
  • biochemical markers
  • left atrial appendage closure
  • TAVI

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 532 KiB  
Article
Predictors of Premature Mortality Following Coronary Artery Bypass Grafting: An Iranian Single-Centre Study
by Fatemeh Pakrad, Rahman Shiri, Azadeh Mozayani Monfared, Ramesh Mohammadi Saleh and Jalal Poorolajal
Healthcare 2024, 12(1), 36; https://doi.org/10.3390/healthcare12010036 - 23 Dec 2023
Viewed by 593
Abstract
Modifiable risk factors play an important role in the premature mortality among patients undergoing coronary artery bypass grafting (CABG). The aim of this study was to examine the factors that influence the early death of patients who had CABG. We conducted a prospective [...] Read more.
Modifiable risk factors play an important role in the premature mortality among patients undergoing coronary artery bypass grafting (CABG). The aim of this study was to examine the factors that influence the early death of patients who had CABG. We conducted a prospective cohort study and followed 2863 patients after their CABG, and collected data on their characteristics and blood tests. We used the Cox proportional hazards regression model in Stata, version 16, to identify the predictors of early mortality. Out of 2863 patients, 162 died during the follow-up period. The survival rate was 99.2% within the first three days after the surgery, 96.2% from the fourth day to the end of the first year, 94.9% at the end of the second year, and 93.6% at the end of the third year. After adjusting for confounding factors, we found that older age (hazard ratio [HR] 1.05, 95% CI 1.02, 1.08 for one year increase in age), obesity (HR 2.16, 95% CI 1.25, 3.72), ejection fraction < 50% (HR 1.61, 95% CI 1.06, 2.44), number of rehospitalizations (HR 2.63, 95% CI 1.35, 5.12 for two or more readmissions), history of stroke (HR 2.91, 95% CI 1.63, 5.21), living in rural areas (HR 1.58, 95% CI 1.06, 2.34), opium use (HR 2.08, 95% CI 1.40, 3.09), and impaired glomerular filtration rate increased the risk of early death after CABG, while taking a beta-blocker (HR 0.59, 95% CI 0.38, 0.91) reduced the risk. We conclude that modifiable risk factors such as excess body mass, high blood glucose, opium use, and kidney dysfunction should be monitored and managed in patients who had CABG to improve their survival outcomes. Full article
(This article belongs to the Special Issue Interventional Cardiology as a Tool for Improving the Quality of Life and Prognosis of Cardiac Patients)
►▼ Show Figures

Figure 1

10 pages, 279 KiB  
Article
Hyperuricemia as a Risk Factor in Hypertension among Patients with Very High Cardiovascular Risk
by Paweł Muszyński, Emil Julian Dąbrowski, Marta Pasławska, Marta Niwińska, Anna Kurasz, Michał Święczkowski, Justyna Tokarewicz, Łukasz Kuźma, Marcin Kożuch and Sławomir Dobrzycki
Healthcare 2023, 11(17), 2460; https://doi.org/10.3390/healthcare11172460 - 03 Sep 2023
Cited by 2 | Viewed by 1098
Abstract
Hypertension remains a global threat to public health, affecting the worldwide population. It is one of the most common risk factors for cardiovascular disease. Today’s treatments focus on creating a hypotensive effect. However, there is a constant search for additional factors to reduce [...] Read more.
Hypertension remains a global threat to public health, affecting the worldwide population. It is one of the most common risk factors for cardiovascular disease. Today’s treatments focus on creating a hypotensive effect. However, there is a constant search for additional factors to reduce the potential of developing hypertension complications. These factors may act as a parallel treatment target with a beneficial effect in specific populations. Some studies suggest that uric acid may be considered such a factor. This study investigated the potential effect of uric acid concentrations over 5 mg/dL on the incidence of hypertension complications among patients with very high cardiovascular risk. A total of 705 patients with hypertension and very high cardiovascular risk were selected and included in the analysis. The patients were divided and compared according to serum uric acid levels. The study showed a higher occurrence of heart failure (OR = 1.7898; CI: 1.2738–2.5147; p = 0.0008), atrial fibrillation (OR = 3.4452; CI: 1.5414–7.7002; p = 0.0026) and chronic kidney disease (OR = 2.4470; CI: 1.3746–4.3558; p = 0.0024) among individuals with serum uric acid levels over 5 mg/dL, males and those with a BMI > 25 kg/m2. These findings suggest that even serum uric acid concentrations over 5 mg/dL may affect the prevalence of hypertension-related complications among patients with very high cardiovascular risk. Full article
(This article belongs to the Special Issue Interventional Cardiology as a Tool for Improving the Quality of Life and Prognosis of Cardiac Patients)
11 pages, 403 KiB  
Article
Comparison of In-Hospital Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction Treated with Ticagrelor or Clopidogrel in the Emergency Department: A Propensity Score Matched Retrospective Cohort Study
by Po-Yao Huang, Hong-Mo Shih, Szu-Wei Huang, Yan-Cheng Pan, Fen-Wei Huang, Wei-Kung Chen and Shao-Hua Yu
Healthcare 2023, 11(16), 2246; https://doi.org/10.3390/healthcare11162246 - 10 Aug 2023
Viewed by 938
Abstract
Background: Dual antiplatelet therapy (DAPT) is a standard treatment option for acute myocardial infarction (AMI). The difference between the efficacy of ticagrelor and clopidogrel in the emergency department (ED) before percutaneous coronary intervention (PCI) remains unknown. The present study compared the in-hospital major [...] Read more.
Background: Dual antiplatelet therapy (DAPT) is a standard treatment option for acute myocardial infarction (AMI). The difference between the efficacy of ticagrelor and clopidogrel in the emergency department (ED) before percutaneous coronary intervention (PCI) remains unknown. The present study compared the in-hospital major adverse cardiovascular event (MACE) rates between patients with AMI treated with clopidogrel and those treated with ticagrelor in the ED before PCI. Methods: We retrospectively collected the data of patients diagnosed as having AMI in the ED. Patients were only included if they had successfully received complete DAPT with aspirin and ticagrelor/clopidogrel in the ED and had undergone PCI. The patients were divided into two groups according to their DAPT regimen. The primary outcome was the rate of in-hospital MACEs. The secondary outcomes included an unexpected return to the ED within 72 h, readmission within 14 d, and revascularization. Results: A total of 1836 patients were enrolled. Patients in the ticagrelor group had a lower in-hospital MACE rate (3.01% versus 7.51%, p < 0.001) and in-hospital mortality rate (2.15% versus 5.70%, p < 0.001) than those in the clopidogrel group. Multivariate logistic regression analysis revealed ticagrelor was independently associated with a lower risk of in-hospital MACEs (odds ratio [OR]: 0.53, 95% CI: 0.32–0.88, p = 0.013). After propensity score matching, the risk of in-hospital MACEs remained significantly lower in the ticagrelor group (OR 0.42, 95% CI: 0.21–0.85, p = 0.016). Conclusion: DAPT with ticagrelor and aspirin in the ED before PCI is associated with a lower in-hospital MACE rate among patients with AMI. Full article
(This article belongs to the Special Issue Interventional Cardiology as a Tool for Improving the Quality of Life and Prognosis of Cardiac Patients)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop